Weight Gain & Cancer Risk; Steppin’ Out After Surgery; Depression in Ovarian Cancer

Weight gain in adulthood may increase a person’s cancer risk by as much as fivefold, according to a Swedish study. (The Guardian)

An updated review of data for nearly 800,000 participants in prostate cancer screening studies concluded that screening likely reduces prostate cancer‐specific mortality and may reduce overall mortality. (Cochrane Library)

Jason Collins, the first openly gay player in the NBA, died of brain cancer earlier this week at age 47. (ESPN)

Every 1,000 steps following surgery can help reduce complications, recovery time, and hospital readmission. (American College of Surgeons)

A tampon-based test for early diagnosis of endometrial cancer showed promise as an aid to ruling out the disease and helping women avoid unnecessary biopsies for abnormal uterine bleeding. (Gynecologic Oncology)

The cost of cancer care imposes a particularly heavy toll on rural patients and survivors. (American Cancer Society)

Sun Pharmaceutical issued a nationwide recall on a lot of its doxorubicin due to a potential risk of glass particles in some medication vials, according to an FDA notice.

News that Revolution Medicines will make its investigational drug daraxonrasib available free of charge to patients with previously treated metastatic pancreatic cancer has U.S. cancer centers scrambling to enroll patients in the early-access program. (Reuters via MSN)

Given “months” to live, this daraxonrasib-treated patient continues to live a full life 2 years after her diagnosis of pancreatic cancer. (NPR)

Psychostimulants, such as methylphenidate, can offer “meaningful relief” for cancer-related fatigue, which affects about three-fourths of all patients with cancer, according to an analysis of nine randomized trials. (Journal of the National Comprehensive Cancer Network)

Is depression overdiagnosed in patients with ovarian cancer? (Cancer)

In muscle-invasive bladder cancer patients ineligible for or who declined cisplatin-based chemotherapy, perioperative durvalumab (Imfinzi) in combination with neoadjuvant enfortumab vedotin (Padcev) improved event-free and overall survival versus standard care in a phase III trial, AstraZeneca said.

Alembic Pharmaceuticals announced tentative FDA approval of its darolutamide tablets as a therapeutic equivalent to the reference drug (Nubeqa), which has approvals for advanced prostate cancer.

From the better-late-than-never file, editors of Pharmacology Biochemistry Behavior have retracted two articles about the discredited alternative cancer treatment cesium dichloride, 42 years after publication. (Retraction Watch)

A North Carolina husband and wife, married for 51 years, share everything, including breast cancer. (People)

A retired Army master sergeant, who pitched “medical and dental care for the rest of your life” to new recruits, now finds himself on the hook for thousands of dollars in follow-up care for throat cancer. (NBC News)